Drug Discovery and Delivery Core

药物发现和递送核心

基本信息

批准号：
10579962
负责人：
JIAN ZUO
金额：
$ 14.33万
依托单位：
CREIGHTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-03-05 至 2026-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10579962
关键词：
Ally Apoptosis Award Biological Assay Biological Availability Cancer Center Support Grant Cell Line Chemical Structure Chemicals Cochlea Collaborations Databases Dedications Disease Dosage Forms Drug Costs Drug Delivery Systems Drug Kinetics Drug Screening Education Eligibility Determination Equipment Extramural Activities Faculty Fees Funding Genetic Transcription Goals Grant Hearing Hearing problem High Pressure Liquid Chromatography Human Resources In Vitro Individual Industry Institution Intellectual Property Laboratories Lead Maps Medical Medical center Mentors Methodology Modernization Mus Nebraska Peptides Pharmaceutical Chemistry Pharmaceutical Preparations Phase Preclinical Testing Reporter Research Research Personnel Research Project Grants Research Support Route Series Services Small Business Innovation Research Grant Strategic Planning Synthesis Chemistry Testing Therapeutic Uses Toxic effect Training Universities Zebrafish boys candidate validation design drug development drug discovery drug use screening efficacy study equipment acquisition experience hearing impairment hearing restoration high throughput screening in silico in vivo instrument lateral line neuromast next generation novel novel therapeutics otoprotectant pharmacokinetics and pharmacodynamics polypeptide prevent programs research clinical testing screening service delivery small molecule therapeutic candidate voucher

项目摘要

ABSTRACT There is a significant unmet medical need to develop pharmacotherapeutics for auditory disorders. Yet, few academic centers in the world are dedicated to these efforts. With a strong focus on pharmacotherapeutics for such disorders in the Translational Hearing Center (THC), our Drug Discovery & Delivery Core (DDDC) aims to establish a state-of-the-art drug development pipeline to facilitate individual research projects in THC. We will leverage projects developed by Research Project Leaders (RPLs) and allied Center Investigators to significantly advance the field of pharmacotherapeutics for auditory disorders. Our DDDC will mentor and train the next generation of hearing researchers and attract new investigators to contribute to this fast advancing field. During Phase 1, DDDC will: 1) develop in silico, in vitro and in vivo high-throughput screens to discover and validate novel therapeutics for auditory disorders; 2) establish a medicinal chemistry pipeline to optimize chemical entities used in research projects or discovered in 1 or in RPLs); 3) establish drug delivery and pharmacokinetic/pharmacodynamic (PK/PD) methodologies; 4) develop a sustainability plan for DDDC services. With strong commitment from Creighton University and neighboring institutes (Boys Town National Laboratory and University of Nebraska Medical Center), the DDDC has already established nearly all necessary equipment and expert personnel. The Director and Co-Directors of DDDC have extensive experience in drug development for auditory disorders, medicinal chemistry and computational structural studies. The sustained impact of the DDDC will be to build a state-of-the-art and highly collaborative center so that additional extramural grants and sponsored programs will gradually cover the main cost of DDDC. We will also emphasize the educational component so that new investigators will become familiar with this fast-moving field of ototherapeutics and maintain the momentum for years to come.

抽象的开发治疗听觉障碍的药物治疗方法存在着巨大的未满足的医疗需求。然而，很少有世界各地的学术中心都致力于这些努力。重点关注药物治疗在转化听力中心 (THC) 中，我们的药物发现和递送核心 (DDDC) 旨在建立最先进的药物开发管道，以促进 THC 的个别研究项目。我们将利用研究项目负责人 (RPL) 和联合中心研究人员开发的项目来显着推进听觉障碍药物治疗领域的发展。我们的 DDDC 将指导和培训下一个一代听力研究人员并吸引新的研究人员为这个快速发展的领域做出贡献。期间第一阶段，DDDC 将：1) 开发计算机、体外和体内高通量筛选，以发现和验证听觉障碍的新疗法； 2）建立药物化学管线，优化化学实体用于研究项目或在 1 或 RPL 中发现）； 3) 建立药物输送和药代动力学/药效学（PK/PD）方法； 4) 制定 DDDC 服务的可持续发展计划。在克赖顿大学和邻近机构（男孩镇国家实验室）的坚定承诺下和内布拉斯加大学医学中心），DDDC 已经建立了几乎所有必要的设备和专家人员。 DDDC的董事和联席董事在药物开发方面拥有丰富的经验用于听觉障碍、药物化学和计算结构研究。的持续影响 DDDC 将建立一个最先进且高度协作的中心，以便获得额外的校外拨款和赞助计划将逐步覆盖 DDDC 的主要费用。我们还将强调教育以便新的研究人员能够熟悉这个快速发展的耳科治疗领域并在未来几年保持这一势头。